1. Home
  2. TECX vs CMPS Comparison

TECX vs CMPS Comparison

Compare TECX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • CMPS
  • Stock Information
  • Founded
  • TECX 2019
  • CMPS 2020
  • Country
  • TECX United States
  • CMPS United Kingdom
  • Employees
  • TECX N/A
  • CMPS N/A
  • Industry
  • TECX
  • CMPS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TECX
  • CMPS Health Care
  • Exchange
  • TECX Nasdaq
  • CMPS Nasdaq
  • Market Cap
  • TECX 387.1M
  • CMPS 364.9M
  • IPO Year
  • TECX 2018
  • CMPS 2020
  • Fundamental
  • Price
  • TECX $23.51
  • CMPS $4.32
  • Analyst Decision
  • TECX Strong Buy
  • CMPS Strong Buy
  • Analyst Count
  • TECX 5
  • CMPS 7
  • Target Price
  • TECX $79.00
  • CMPS $17.00
  • AVG Volume (30 Days)
  • TECX 230.2K
  • CMPS 1.9M
  • Earning Date
  • TECX 08-07-2025
  • CMPS 07-31-2025
  • Dividend Yield
  • TECX N/A
  • CMPS N/A
  • EPS Growth
  • TECX N/A
  • CMPS N/A
  • EPS
  • TECX N/A
  • CMPS N/A
  • Revenue
  • TECX N/A
  • CMPS N/A
  • Revenue This Year
  • TECX N/A
  • CMPS N/A
  • Revenue Next Year
  • TECX N/A
  • CMPS N/A
  • P/E Ratio
  • TECX N/A
  • CMPS N/A
  • Revenue Growth
  • TECX N/A
  • CMPS N/A
  • 52 Week Low
  • TECX $13.70
  • CMPS $2.25
  • 52 Week High
  • TECX $61.07
  • CMPS $8.54
  • Technical
  • Relative Strength Index (RSI)
  • TECX 56.50
  • CMPS 53.62
  • Support Level
  • TECX $21.31
  • CMPS $4.17
  • Resistance Level
  • TECX $23.12
  • CMPS $4.47
  • Average True Range (ATR)
  • TECX 1.53
  • CMPS 0.30
  • MACD
  • TECX 0.13
  • CMPS -0.03
  • Stochastic Oscillator
  • TECX 71.85
  • CMPS 45.98

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Share on Social Networks: